# This variant was designated A.27.RN according to its phylogenetic clade classification. It emerged in parallel 
# with the B.1.1.7 variant, increased to >50% of all SARS-CoV-2 variants by week five. Subsequently it decreased 
# to <10% of all variants by calendar week eight when B.1.1.7 had become the dominant strain. Antibodies induced 
# by BNT162b2 vaccination neutralized A.27.RN but with a two-to-threefold reduced efficacy as compared to the 
# wild-type and B.1.1.7 strains.
# Mallm et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.27.21254849v1
L18F;L452R;N501Y;A653V;H655Y;D796Y;G1219V

# The study demonstrated 1.92 and 1.09 fold reductions (ELISA) in the neutralizing titer against B.1.1.28.2 (P2)
# variant (n=2 authentic virus) in comparison with prototype D614G variant with 42 sera of BBV152 (a.k.a. Covaxin) vaccine recipients 
# 2mo post-booster and 19 natural infections respectively.
# PG: exact P.2 sequences were not given, using the common defining SNPs
# Sapkal et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.30.441559v1
E484K;F565L;D614G;V1176F

# After one dose, individuals with prior infection showed enhanced T cell immunity, 
# antibody secreting memory B cell response to spike and neutralizing antibodies effective 
# against B.1.351 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior 
# infection showed reduced immunity against variants. B.1.351 spike mutations 
# resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte 
# antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.
# Reynolds et al. (2021) https://science.sciencemag.org/content/early/2021/04/29/science.abh1282
D80A;L242del;A243del;L244del;R246I;K417N;E484K;N501Y;A701V

# ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose,
# with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).
# Gallagher et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1
D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose,
# with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).
# Gallagher et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I;V1176F

# After one dose, individuals with prior infection showed enhanced T cell immunity, 
# antibody secreting memory B cell response to spike and neutralizing antibodies effective 
# against B.1.1.7 (authentic cell culture supernatants). By comparison, HCW receiving one vaccine dose without prior 
# infection showed reduced immunity against variants. B.1.1.7 spike mutations 
# resulted in increased, abrogated or unchanged T cell responses depending on human leukocyte 
# antigen (HLA) polymorphisms. Study was 26 each post-infection and post first dose HCWs.
# Reynolds et al. (2021) https://science.sciencemag.org/content/early/2021/04/29/science.abh1282
# ELISpot assays show T cell neutralization reduced by 15.4% in this B.1.1.7 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose,
# with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).
# Gallagher et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

# Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration
# for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.
# Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1
L5F;T95I;D253G;S477N;D614G;A701V

# Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both
# IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.
# Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1
L5F;T95I;D253G;E484K;D614G;A701V

# No significant change in virus neutralzation by 18 Pfizer two dose vaccinnee sera compared to B.1.1.7.
# PG: results without include A27S seem generaluzable as this is not a lineage defining mutation.
# Zuckerman et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1
D614G;P681H

# Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was
# reduced ~2.8-fold compared to wildtype (D614G) S. 
# It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose). 
# Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech
# BNT162b2-elicited plasma neutralizing activity.
# McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
S13I;W152C;L452R

# VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose.
# Cell fusion proficiency was unchanged.
# Hoffman et al. (2021) https://doi.org/10.1016/j.cell.2021.03.036
# Lineage B.1.1.7 spike–pseudotyped VSV was tested for neutralization vs Wuhan reference genome pseudotype in 40 sera collected
# 7 or 21 days post-booster dose. Statistically signficant change (22%) in neutralization was observed among the 26 sera from those <=55yo, 
# but not in the 14 sera from those >55yo. A ~20% change is not considered immunologically significant historically in influenza antiboduy studies. 
# Muik et al. (2021) https://science.sciencemag.org/content/371/6534/1152
# Vaccine elicited antibodies neutralized virus with the B.1.1.7 spike protein with titers similar to D614G virus. Serum specimens 
# from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater than convalescent sera.
# Tada et al. (2021) https://doi.org/10.1101/2021.02.05.430003
H69del;V70del;Y144del;N501Y;A570D;P681H;T716I;S982A;D1118H

# VSV pseudotype B.1.351 showed 7.85-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose.
# Cell fusion proficiency was slight impaired.
# Hoffman et al. (2021) https://doi.org/10.1016/j.cell.2021.03.036
# B.1.351 pseudotyped lentivirus showed 3.4 and 3.8x reduction in IC50 serum dilution concentration
# for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.
# Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1
# Vaccine elicited antibodies neutralized virus with the B.1.351 spike protein had an average 3-fold reduction in titer (1:500), 
# a titer that was still higher than the average titer with which convalescent sera neutralized D614G (1:139). Serum specimens 
# from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater 
# than convalescent sera.
# Tada et al. (2021) https://doi.org/10.1101/2021.02.05.430003
D80A;L242del;A243del;L244del;R246I;K417N;E484K;N501Y;A701V

# VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose.
# Cell fusion proficiency was slight impaired.
# Hoffman et al. (2021) https://doi.org/10.1016/j.cell.2021.03.036
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;H655Y;T1027I;V1176F

# Neutralization assays of B.1.1.7 virus showed a reduction of 2.5-fold (14 days post 2nd dose AstraZeneca, n=15), 2.1-fold (28 days post 2nd dose AstraZeneca, n=10), 
# and 3.3-fold (7-17 days post 2nd dose Pfizer-BioNTech, n=25).
# PG: Note that D1119H was included in the original paper, I am assuming that's a typo and it should be D1118H
# Supasa et al. (2021) https://doi.org/10.1016/j.cell.2021.02.033
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

# Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9 
# days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
D614G

# Pseudotyped B.1.1.7 virus has reduced neutralization activity vs wild type: 2.1x (30 sera Pfizer median 9 days post 2nd dose) 
# and 2.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.
# Note that Y145del was actually noted in the paper as the effect of their DNA construct, but this is 
# equivalent at the protein level to the more commonly annotated Y144del.
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H 

# Pseudotyped B.1.1.298 virus has reduced neutralization activity vs wild type: 1.4x (30 sera Pfizer median 9 days post 2nd dose) 
# and 1.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
H69del;V70del;Y453F;D614G;I692V;M1229I

# Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9 
# days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
S13I;W152C;L452R;D614G

# Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose) 
# and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
E484K;D614G;V1176F

# Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) 
# and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I;V1176F

# Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose) 
# and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.
# Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have 
# detectable neutralization of at least one of the B.1.351 variants. 
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose) 
# and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.
# Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have 
# detectable neutralization of at least one of the B.1.351 variants. 
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
L18F;D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# Pseudotyped B.1.351 v3 virus has reduced neutralization activity vs wild type: 42.4x (30 sera Pfizer median 9 days post 2nd dose) 
# and 19.2x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.
# Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have 
# detectable neutralization of at least one of the B.1.351 variants. 
# Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013
D80A;L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after 
# the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001).
# For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing 
# interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).
# Zhou et al. (2021) https://doi.org/10.1016/j.cell.2021.02.037
# The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa, 
# where 92.6% of infections are estimated to have been B.1.351.
# Novavax (2021) https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf
# The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was 
# reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in 
# hospitalization risk remains across variants after 28 days post-vaccination.
# https://mg.co.za/coronavirus-essentials/2021-03-24-single-dose-jj-janssen-covid-19-vaccine-hopes-to-speed-up-sas-vaccination-programme/
# A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however, 
# vaccine efficacy against severe Covid-19 is undetermined.
# Madhi et al. (2021) https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1
D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample.
# Contrast this with 1.4-fold reduction for just the pseudovirus combination of "key" B.1.351 mutations K417N+E484K+N501Y.
# WA1 and B.1.351 FRNT50 titers correlated weakly at the
# individual level, with some individual’s serum potently neutralizing WA1 while having
# FRNT50 for B.1.351 below the assay limit of detection (1:20).
# Bates et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1
L18F;D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) 
# against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.
# Bates et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1
K417N;E484K;N501Y

# Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) 
# against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.
# Bates et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1
# Human sera from 6 single-dose Pfizer vaccinated individuals (47-68 days post-dose) can neutralize both the reference 
# USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.
# Rathnasinghe et al. (2021) https://dx.doi.org/10.1101%2F2021.01.19.21249592
N501Y

# Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.1.7 sample.
# Contrast this with 1.3-fold reduction for just the pseudovirus combination of "key" B.1.1.7 mutation N501Y.
# Bates et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1
H69del;V70del;Y145del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

# Sera after the second dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 + E484K 
# variant of ~6.7x, markedly higher than B.1.1.7 alone. For first dose sera, a 9.7x drop was observed.
# Collier et al. (2021) https://www.nature.com/articles/s41586-021-03412-7
H69del;V70del;Y144del;E484K;N501Y;A570D;P681H;T716I;S982A;D1118H

# 20/29 sera after the first dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 variant of 3.2 ± 5.7.
# After the second dose, the GMT was markedly increased compared with the first-dose titres, with a fold change of 1.9 ± 0.9 (mean ± s.d.).
# Neutralization GMT of 27 subjects post-infection was considerably higher (stronger) than after the second Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.
# Collier et al. (2021) https://www.nature.com/articles/s41586-021-03412-7
H69del;V70del;Y144del;N501Y;A570D;P681H;T716I;S982A;D1118H

# Pzifer vaccinees that tested positive at least a week after the second dose were indeed disproportionally infected with B.1.351, 
# as compared with unvaccinated individuals (odds ratio of 8:1), but were all infected before 14 days post second vaccination.
# Kustin et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.06.21254882v2
L18F;D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;Q677H;R682W;A701V

# In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed 
# ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with 
# a higher ID50 reciprocal value.
# In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed 
# ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with 
# similar variant ID50 reciprocal value.
# Wang et al. (2021) https://dx.doi.org/10.1101%2F2021.03.01.433466
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y

# Monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. 
# In a mouse study, primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage, 
# while mRNA-1273.211 was most effective at providing broad cross-variant neutralization. In addition, these results demonstrated a third dose of 
# mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. 
# Wu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.13.439482v1
# Four fold reduction in neutralization efficiency was observed in sera of ferrets post-vaccination with 
# INO-4800 (DNA plasmid pGX9501 encoding full length Spike).
# Riddell et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.17.440246v1
# In human sera 8 weeks post-vaccination with INO-4800, a ~7-fold reduction in B.1.351 neutralization was observed.
# Andrade et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1
L18F;D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;Q677H;R682W;A701V

# The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases
# was proportionally in line with lineage prevalence in Northen California during the study period,
# suggesting no effect of these variants on immune escape.
# Jacobson et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2
L452R;N501Y

# The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases
# was proportionally in line with lineage prevalence in Northen California during the study period,
# suggesting no effect of these variants on immune escape.
# Jacobson et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2
L452R

# The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases
# was proportionally in line with lineage prevalence in Northen California during the study period,
# suggesting no effect of these variants on immune escape.
# Jacobson et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2
N501Y

# Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency 
# (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one 
# relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.
# Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
D80A;D215G;K417N;E484K;N501Y;A701V

# Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency 
# (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one 
# relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.
# Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
# In human sera 8 weeks post-vaccination with INO-4800, a ~2-fold reduction in P.1 neutralization was observed.
# Andrade et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1
# Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine 
# effectiveness, 49.6%; 95% CI, 11.3 - 71.4) in the odds of 
# symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose.
# Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.
# Hitchlings et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;H655Y;T1027I

# Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents. 
# Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages.
# Yadav et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.23.441101v1
G142D;E154K;L452R;E484Q;D614G;P681R;Q1071H

# 6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.
# Deng et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1
S13I;W152C;L452R

# In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, 
# ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.
# Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
E484K

# In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, 
# a modest decrease in neutralization by vaccine plasma was observed.
# Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
N501Y

# In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, 
# a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.
# Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
# In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases, 
# titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.
# Wu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1
K417N;E484K;N501Y

# Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.
# Liu et al. (2021) https://www.nejm.org/doi/full/10.1056/NEJMc2102017
D80A;D215G;L242del;A243del;L244del;K417N;E484K;N501Y;D614G;A701V

# The neutralizing activity of vaccine was significantly lower against B.1.351 (12.4x in twelve Moderna-recipient sera; 10.3x in ten Pfizer-recipient sera).
# PG: this is a larger list of B.1.351 than modeled by Wang et al. (2021) by including L18F and R246I, and is less effective at neutralizing.
# Wang et al. (2021) https://www.nature.com/articles/s41586-021-03398-2
L18F,D80A,D215G,L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# The neutralizing activity of vaccine was significantly lower against B.1.351 in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)
# Chen et al. (2021) https://www.nature.com/articles/s41591-021-01294-w 
D80A,L242del;A243del;L244del;R246I;K417N;E484K;N501Y;D614G;A701V

# The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with 
# the BNT162b2 mRNA vaccine. (Fig. 4)
# Chen et al. (2021) https://www.nature.com/articles/s41591-021-01294-w 
L18F;T20N;P26S;D138Y;R190S;K417T;E484K;N501Y;D614G;H655Y;T1027I;V1176F

# The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with 
# the BNT162b2 mRNA vaccine. (Fig. 4)
# PG: This is in stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774).
# Chen et al. (2021) https://www.nature.com/articles/s41591-021-01294-w
# In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization.
# This variant combination showed the highest reduction, but the magnitude of the differences was small 
# compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.
# Xie et al. (2021) https://www.nature.com/articles/s41591-021-01270-4
E484K;N501Y

# The neutralizing activity of vaccine was somewhat lower against B.1.1.7 in sera tested from most of the 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4)
# Chen et al. (2021) https://www.nature.com/articles/s41591-021-01294-w 
H69del;V70del;Y144del;Y145del;N501Y;A570D;D614G;P681H

# Pseudotyped B.1.1.7 Spike variants lentivirus.
# 3.5x reduction in neutralization with Moderna vaccinated patient sera after 29 days (1st dose).
# 2.0x reduction in neutralization with Moderna vaccinated patient sera after 57 days (2nd dose).
# 2.1x reduction in neutralization with Novavax Phase 1 post-vaccination sera.
# Shen et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2
H69del;V70del;Y144del;N501Y;A570D;D614G;P681H;T716I;S982A;D1118H

